Affimed (AFMD)

Affimed (AFMD) Stock Price & Analysis


AFMD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.55 - $3.40
Previous Close$0.75
Average Volume (3M)772.44K
Market Cap
Enterprise Value-$59.35M
Total Cash (Recent Filing)€190.29M
Total Debt (Recent Filing)€18.19M
Price to Earnings (P/E)-1.1
Aug 09, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding149,340,000
10 Day Avg. Volume1,055,486
30 Day Avg. Volume772,441
Standard Deviation0.34
Financial Highlights & Ratios
Price to Book (P/B)0.86
Price to Sales (P/S)2.73
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside465.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Affimed’s price range in the past 12 months?
Affimed lowest stock price was $0.55 and its highest was $3.40 in the past 12 months.
    What is Affimed’s market cap?
    Currently, no data Available
    When is Affimed’s upcoming earnings report date?
    Affimed’s upcoming earnings report date is Aug 09, 2023 which is in 62 days.
      How were Affimed’s earnings last quarter?
      Affimed released its earnings results on May 23, 2023. The company reported -$0.225 earnings per share for the quarter, missing the consensus estimate of -$0.205 by -$0.019.
        Is Affimed overvalued?
        According to Wall Street analysts Affimed’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Affimed pay dividends?
          Affimed does not currently pay dividends.
          What is Affimed’s EPS estimate?
          Affimed’s EPS estimate is -$0.2.
            How many shares outstanding does Affimed have?
            Affimed has 149,339,340 shares outstanding.
              What happened to Affimed’s price movement after its last earnings report?
              Affimed reported an EPS of -$0.225 in its last earnings report, missing expectations of -$0.205. Following the earnings report the stock price went down -9.346%.
                Which hedge fund is a major shareholder of Affimed?
                Among the largest hedge funds holding Affimed’s share is Baker Bros Advisors LP. It holds Affimed’s shares valued at 5M.


                  Affimed Stock Smart Score

                  The Affimed stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description


                  Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.


                  Top 5 ETFs holding AFMD

                  Market Value
                  Smart Score
                  iShares NASDAQ US Biotechnology UCITS ETF
                  Invesco Nasdaq Biotechnology ETF
                  Up to five ETFs with an Outperform Smart Score that hold AFMD. The ETFs are listed according to market value of AFMD within the ETF


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Onconova Therapeutics
                  Molecular Templates

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis